- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 17 Jul 20 424B4 Prospectus supplement with pricing info
- 17 Jul 20 EFFECT Notice of effectiveness
-
13 Jul 20 S-1/A IPO registration (amended)
- 26 Jun 20 S-1 IPO registration
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
The Board of Directors
ALX Oncology Limited:
We consent to the use of our report dated May 5, 2020, except for the retroactive effect of the reverse stock split as described under the heading ‘Reverse Stock Split’ in Note 13, which is as of July 13, 2020, with respect to the consolidated balance sheets of ALX Oncology Limited as of December 31, 2018 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred shares and shareholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2019, and the related notes, included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
San Francisco, California
July 13, 2020